These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23594083)

  • 1. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
    Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
    Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
    Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of asunaprevir resistance in HCV NS3/4A protease.
    Soumana DI; Ali A; Schiffer CA
    ACS Chem Biol; 2014 Nov; 9(11):2485-90. PubMed ID: 25243902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
    Lampa A; Alogheli H; Ehrenberg AE; Åkerblom E; Svensson R; Artursson P; Danielson UH; Karlén A; Sandström A
    Bioorg Med Chem; 2014 Dec; 22(23):6595-6615. PubMed ID: 25456385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
    McCauley JA; McIntyre CJ; Rudd MT; Nguyen KT; Romano JJ; Butcher JW; Gilbert KF; Bush KJ; Holloway MK; Swestock J; Wan BL; Carroll SS; DiMuzio JM; Graham DJ; Ludmerer SW; Mao SS; Stahlhut MW; Fandozzi CM; Trainor N; Olsen DB; Vacca JP; Liverton NJ
    J Med Chem; 2010 Mar; 53(6):2443-63. PubMed ID: 20163176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.
    Nageswara Rao D; Zephyr J; Henes M; Chan ET; Matthew AN; Hedger AK; Conway HL; Saeed M; Newton A; Petropoulos CJ; Huang W; Kurt Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2021 Aug; 64(16):11972-11989. PubMed ID: 34405680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
    Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
    Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
    Summa V; Ludmerer SW; McCauley JA; Fandozzi C; Burlein C; Claudio G; Coleman PJ; Dimuzio JM; Ferrara M; Di Filippo M; Gates AT; Graham DJ; Harper S; Hazuda DJ; Huang Q; McHale C; Monteagudo E; Pucci V; Rowley M; Rudd MT; Soriano A; Stahlhut MW; Vacca JP; Olsen DB; Liverton NJ; Carroll SS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4161-7. PubMed ID: 22615282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.
    Parsy CC; Alexandre FR; Bidau V; Bonnaterre F; Brandt G; Caillet C; Cappelle S; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos LB; Leroy F; Liuzzi M; Loi AG; Moulat L; Chiara M; Rahali H; Roques V; Rosinovsky E; Savin S; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5427-36. PubMed ID: 26410074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325.
    Rudd MT; Butcher JW; Nguyen KT; McIntyre CJ; Romano JJ; Gilbert KF; Bush KJ; Liverton NJ; Holloway MK; Harper S; Ferrara M; DiFilippo M; Summa V; Swestock J; Fritzen J; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; McClain S; McHale C; Stahlhut MW; Black S; Chase R; Soriano A; Fandozzi CM; Taylor A; Trainor N; Olsen DB; Coleman PJ; Ludmerer SW; McCauley JA
    ChemMedChem; 2015 Apr; 10(4):727-35. PubMed ID: 25759009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
    Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.